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Pharmacodynamics and Pharmacokinetics Following
Once-Daily and Twice-Daily Dosing of Tiotropium
Respimat in Asthma Using Standardized
Sample-Contamination Avoidance
Kai-Michael Beeh, MD,1 Anne-Marie Kirsten, MD,2 Daniel Dusser, MD,3 Ashish Sharma, PhD,4
Piet Cornelissen, PhD,5 Ralf Sigmund, Dipl.-Math.oec,6 Petra Moroni-Zentgraf, MD,5 and Ronald Dahl MD7
Abstract
Background: This study was conducted to confirm the 24-hour bronchodilator efficacy and pharmacokinetic
profile of once-daily tiotropium Respimat 5lg add-on to inhaled corticosteroids (ICS) in adults with symp-
tomatic asthma. It used a trial protocol designed to minimize the risk of pharmacokinetic sample contamination
resulting from improper sampling procedure, sample handling, or device handling during priming and subse-
quent inhalation procedure.
Methods: A Phase II, randomized, double-blind, two-way crossover study (NCT01696071) comparing two
daily dosing regimens of tiotropium for 4 weeks, once-daily 5lg (evening dosing) or twice-daily 2.5lg
(morning and evening dosing), as add-on to maintenance therapy with ICS (400–800lg budesonide or
equivalent) as controller medication. There was no washout between treatment periods.
Results: An increase in the area under the curve of the 24-hour forced expiratory volume in 1 second profile
from study baseline was observed following once-daily tiotropium 5lg (217mL) and twice-daily 2.5lg
(219mL), with no difference between the two regimens (-2mL [95% confidence interval: -38, 34]). In a subset
of the study population, total tiotropium exposure, expressed as area under the plasma concentration versus time
curve over 24 hours, was comparable between dosing regimens. Unexpected tiotropium plasma levels were
observed in two patients, possibly because of contamination.
Conclusions: The observed bronchodilator efficacy over 24 hours was similar with once-daily tiotropium 5lg
and twice-daily 2.5lg as add-on to ICS therapy, supporting the suitability of once-daily dosing to provide
sustained improvements in lung function in adults with symptomatic asthma.
Keywords: asthma, blood-sampling contamination, pharmacodynamics, pharmacokinetics, tiotropium,
Respimat
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Introduction
Despite current treatment recommendations withinhaled corticosteroids (ICS) or ICS with long-acting
b2-agonists, about half of asthma patients are classified as
having poorly controlled disease.(1–3) Poorly controlled
asthma places a burden on healthcare systems, with health-
care costs rising with increasing asthma severity and the
occurrence of asthma exacerbations.(4,5) Patients with un-
controlled asthma also suffer from poorer health-related
quality of life, with decreased work productivity(6) and in-
creased risk of anxiety and depression.(7)
Tiotropium, a long-acting anticholinergic bronchodilator,
has recently undergone investigation as an add-on mainte-
nance therapy in patients with symptomatic asthma. Ker-
stjens and colleagues have shown that once-daily tiotropium
5 lg, delivered via the Respimat Soft Mist inhaler
(Boehringer Ingelheim, Ingelheim am Rhein, Germany) as
add-on to ICS and long-acting b2-agonists, significantly
increased the time to the first severe exacerbation and pro-
vided modest sustained bronchodilation in adult patients
with severe symptomatic asthma.(8) Similarly, once-daily
tiotropium 5 lg and 2.5 lg, as add-on to ICS, both provided
improvements in lung function and asthma control, com-
parable with twice-daily salmeterol 50lg, in patients with
moderate symptomatic asthma.(9)
The potential effect of the daily dosing regimen of tio-
tropium on improvements in lung function was addressed in
a Phase II study evaluating and comparing the 24-hour
forced expiratory volume in 1 second (FEV1) profiles fol-
lowing two different dosing regimens in patients with
symptomatic asthma.(10) In each treatment period of the
two-way crossover study, patients received either once-daily
tiotropium 5 lg administered in the evening with matching
placebo Respimat inhaler in the morning, or tiotropium
2.5 lg administered in the morning and evening. Improve-
ments in lung function were sustained and similar for both
daily dosing regimens, supporting tiotropium as a once-daily
bronchodilator in patients with symptomatic asthma.
However, the pharmacokinetic (PK) assessments revealed
tiotropium plasma levels in some samples, which was not
expected taking into account the dosing regimen of the study
drug, and was therefore considered to be caused by con-
tamination. Contamination itself can be caused by a variety
of factors, including laboratory errors during the PK blood-
sampling procedure and sample handling, or improper de-
vice handling during priming and the subsequent inhalation
procedure.(11) While it was concluded that the contamina-
tion did not affect the robustness of the PK or efficacy
outcomes, it cannot be ruled out that unexpected tiotropium
levels in plasma samples could be caused by randomization
errors with, for example, twice-daily inhalation from the
same evening device delivering a 5 lg dose instead of one
inhalation of tiotropium 5 lg in the evening and one inha-
lation from the placebo inhaler in the morning.
Although contamination of PK blood and urine samples
with inhaled drugs has not been widely studied, it has been
reported in a number of trials in other therapy areas, with
sources of contamination including personal contamination
from the research staff (contamination from human hair)(12)
or because of certain laboratory practices (ethylenediami-
netetraacetic acid contamination of blood sample)(13) or
clinical practices (contamination of blood samples with
testosterone-containing gels).(14) Particles of some inhaled
therapeutic agents, such as salbutamol sulfate, ipratropium
bromide, and fluticasone propionate, are known for their
tendency to agglomerate and adhere to many surfaces(15–17)
and could represent a source of sample contamination in
laboratory settings. It is therefore important that preventa-
tive steps are taken at all stages of a study that includes PK
assessments, from drug administration to blood sampling
and analysis,(18) to avoid the detection of a study drug in
placebo samples which would jeopardize the validity of
subsequent analyses.
The objective of the present study was to confirm the 24-
hour FEV1 and PK profiles of once-daily tiotropium 5 lg
and twice-daily 2.5 lg observed in a previous Phase II,
randomized, double-blind, placebo-controlled, three-way
crossover study,(10) using a trial protocol designed to reduce
errors caused by improper use of the inhaler (i.e., switching
between morning and evening inhalers) and introducing
precautionary steps to minimize the risk of contamination.
Materials and Methods
Study design
This was a Phase II, randomized, double-blind, two-way
crossover study (ClinicalTrials.gov identifier: NCT01696071)
conducted in 22 sites in Austria, Germany, Hungary, and
Slovenia. Patients entered a 28-day screening period, after
which eligible patients were randomized to two 4-week
treatment periods, with no washout between treatments,
and with a 21-day follow-up period (Fig. 1). The study was
performed in accordance with the principles of the De-
claration of Helsinki and the International Conference on
Harmonisation for Good Clinical Practice Guidelines. The
patient information sheet and consent form were reviewed
and approved by each participating institution’s review
board. Before participation in the study, written, informed
consent was obtained from all individual participants in-
cluded in the study.
Study treatment
Tiotropium and placebo were both delivered using the
Respimat Soft Mist inhaler; each treatment was deliv-
ered via two inhalations, irrespective of dose. There were
two treatment sequences, and each patient was randomly
assigned to sequence 1 (tiotropium 5 lg administered once
daily in the evening and placebo in the morning for 4 weeks,
followed by tiotropium 2.5 lg administered in the morning
and evening for 4 weeks) or sequence 2 (tiotropium 2.5 lg
administered twice daily for 4 weeks, followed by tio-
tropium 5 lg administered once daily for 4 weeks). Patients
continued maintenance treatment with ICS (a daily dose of
400–800lg budesonide or equivalent) throughout the study.
To reduce the potential risks of switching inhalers be-
tween morning and evening administrations, simplified la-
beling for the medication kit was introduced so that inhalers
intended for morning use were labeled with a sun symbol
and a yellow label, while those for evening use were labeled
with a moon symbol and a blue label.
Medications permitted for the treatment of acute asthma
exacerbations during the study included salbutamol
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(albuterol) metered-dose inhaler as needed (with ‡8-hour
washout before all visits, including lung function tests), a
temporary increase in the dose of ICS or the addition of a
systemic steroid, and a short-acting theophylline.
Non-permitted maintenance medications after screening
(Visit 1) included systemic steroids, long-acting b2-agonists,
anticholinergics other than the study drug, methylxanthines,
anti-immunoglobulin E treatment, leukotriene receptor an-
tagonists, and cromones.
Study population
The study population included patients with similar base-
line characteristics, as previously described,(10) but using a
different cohort of patients. Inclusion criteria included male
and female patients aged 18–75 years who had at least a 3-
month documented history of asthma, with an initial con-
firmed diagnosis before the age of 40 years, and treated with
stable-dose ICS (400–800 lg budesonide or equivalent) for at
least 4 weeks before screening. Patients had to have a pre-
bronchodilator FEV1 of 60%–90% of predicted normal at
screening, and bronchodilator reversibility defined as an
FEV1 increase of ‡12% and ‡200mL 10min before and 15–
30min after inhalation of 400 lg salbutamol. Patients were
required never to have smoked, or had to be ex-smokers with a
history of <10 pack-years who stopped smoking ‡1 year be-
fore enrollment. All patients had to be symptomatic at
screening and randomization, as defined by a seven-question
Asthma Control Questionnaire mean score of ‡1.5. Major
exclusion criteria included significant disease other than
asthma (e.g., chronic obstructive pulmonary disease).
Study end points
All FEV1-based end points were analyzed as responses,
defined as the change from study baseline at randomization
before inhalation of the first dose of study drug.
The primary efficacy end point was FEV1 area under the
curve (AUC) from 0 to 24 hours (FEV1 AUC(0–24h)), mea-
sured after inhalation of the last evening dose at the end of
each 4-week period of randomized treatment. FEV1 AUC(0–24h)
was defined as the mean FEV1 over the 24-hour observation
period (0–24 hours) normalized for time after inhalation
of the last evening dose of study drug and calculated using
the trapezoidal rule divided by the corresponding duration
(i.e., 24 hours) to provide results expressed in liters. FEV1
AUC(0–24h) response was defined as the change in FEV1
AUC(0–24h) from the common study baseline FEV1 value,
which was the measurement obtained before the first even-
ing dose of randomized study drug.
Secondary lung function end points included peak FEV1
measured within 24 hours of the last evening inhalation at
the end of each 4-week period, FEV1 AUC from 0 to 12 hours
(FEV1 AUC(0–12h)), FEV1 AUC from 12 to 24 hours (FEV1
AUC(12–24h)), and trough FEV1, measured 10min before the
last evening inhalation at the end of each 4-week period. Pre-
dose morning and evening peak expiratory flow was evalu-
ated based on the weekly mean of the last week of each
4-week treatment period and was measured by patients at
home using theAM3 device (eResearch TechnologyGmbH,
Estenfeld, Germany).
In a subset of 35 patients who had been randomized to
both dosing regimens, PK end points included maximum
concentration at steady state in plasma (morning and
evening separately for twice-daily administration), area
under the tiotropium plasma concentration–time curve at
steady state, time from dosing to maximum plasma con-
centration, and amount of drug eliminated unchanged in
urine over a 24-hour period.
Study assessments
Spirometry (MasterScope CT; eResearch Technology
GmbH) was conducted at all clinic visits. Qualifying lung
function testing was conducted at screening, and FEV1,
forced vital capacity, and peak expiratory flow were per-
formed at randomization before inhalation of the first
evening dose of study drug. At Visits 4 and 6 (Fig. 2), lung
function testing started at approximately the same time of
day (– 30min), with visits scheduled to enable the start of
the evening pre-dose tests between the hours of 17:50 and
19:50. At each time point, spirometric maneuvers were
conducted in triplicate. The highest FEV1 from an accept-
able maneuver was recorded, along with the time.
Lung function tests started 10min before evening dosing
of the study drug at the end of each 4-week treatment period
(Visits 4 and 6) (Fig. 1). Subsequently, lung function tests
were performed at 0.5, 1, 2, 3, 4, and 11.8 hours after
Randomization
FIG. 1. Study design. Sequence 1: tiotropium 5 lg administered once daily in the
evening and placebo in the morning for 4 weeks, followed by tiotropium 2.5 lg admin-
istered in the morning and evening for 4 weeks. Sequence 2: tiotropium 2.5 lg adminis-
tered twice daily for 4 weeks followed by tiotropium 5 lg administered once daily for 4
weeks. Patients (n = 98) were randomized 1:1 to sequence 1 or sequence 2. BID, twice
daily; ICS, inhaled corticosteroids; QD, once daily.
408 BEEH ET AL.
inhalation of the last evening dose of study drug. Morning
dosing was performed 12 hours after evening dosing, and
lung function assessments were continued at 12.5, 13, 14,
15, 16, 18, 20, 22, 23, and 23.8 hours after evening dosing.
At Visits 3 and 5 (Weeks 2 and 6, respectively) (Fig. 1),
patients were followed up to record study drug adherence,
concomitant medications, and adverse events.
Patients performed twice-daily peak expiratory flow mea-
surements at home at approximately the same time of the day
using the AM3 device. Morning and evening peak expiratory
flow measurements were performed before inhalation of the
maintenance ICSdose and study drug. Patients performed three
maneuvers with the AM3 device while standing, and the
highest value was used for evaluation.
For PK analysis, blood samples were collected at Visits 4
and 6 (steady state) 15min before administration of the
evening dose of study drug (self-administered in the inha-
lation room between the hours of 18:00 and 20:00) and after
2, 5, 7, 10, 15, and 30min, and then 1, 3, and 11.75 hours.
This was followed by administration of the morning dose
(self-administered in the inhalation room between 06:00 and
08:00, 12 h after administration of the evening dose –5min),
FIG. 2. Pharmacokinetic procedures and lung function testing at Visits 4 and 6. Phar-
macokinetic subset (n= 35). aPre-dose urine sample obtained from urine collected in the
last hour before study drug administration. bAll urine voided during the 0- to 6-hour post-
dose interval. cAll urine voided during the 6- to 12-hour post-dose interval. dAll urine
voided during the 12- to 24-hour post-dose interval. eForced expiratory volume in
1 second, forced vital capacity, and peak expiratory flow completed using the Master-
Scope CT. fLung function testing performed at 10:00, 11:00, 13:00, 15:00, 17:00, 18:00,
and 18:50. gAdministration of a patient’s own inhaled corticosteroids according to his/her
regular dosing. PK, pharmacokinetics.
z
FIG. 3. CONSORT diagram. BID, twice daily; QD, once daily.
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with subsequent blood sampling carried out after 12 h + 2, 5,
7, 10, 15, and 30min, and after 13, 15, and 23.75 h relative
to the evening dose. Urine collected pre-dosing (-1 hour to
0) and all urine voided post-dosing were collected over 24h
post-dose (Fig. 2). A protocol detailing the preventive measures
taken to avoid contamination of plasma and urine samples was
followed (see Supplementary Table 1; supplementary material
is available online at www.liebertpub.com/jamp).
Plasma and urine concentrations of tiotropium were de-
termined by a validated assay using high-performance liquid
chromatography coupled to tandem mass spectrometry us-
ing electrospray ionization in the positive-ion mode, per-
formed at NUVISAN GmbH, Neu-Ulm, Germany. Safety
and tolerability were assessed by the occurrence of adverse
events.
Pharmacokinetic analyses
Non-compartmental PK analyses were carried out using
a validated software program, WinNonlin (Professional
Version 5.2; Pharsight Corporation, Mountain View, CA,
USA). AUC values were calculated using the linear up/log
down algorithm.
Statistical analyses
Efficacy data are reported for the full analysis set, defined
as all treated patients who had baseline data and at least one
on-treatment efficacy measurement after 4 weeks of treat-
ment within a treatment period. The PK subset was defined
as all patients who provided samples for the evaluation of
tiotropium PK in blood and urine. Safety data are reported
for the treated set, defined as all randomized patients who
received at least one dose of study drug.
Assuming a standard deviation of 225mL for within-
patient difference of FEV1 AUC(0–24h), a sample size of 92
randomized patients to obtain 82 completed patients was
needed for a full crossover design to detect a mean differ-
ence between the two active treatments within -50mL,
50mL with a probability of 95%. AUC was calculated by
using the trapezoidal rule divided by the observation time
(24 hours). AUC values were also calculated relative to the
evening dosing, with AUC(0–12h) referring to the night-time
and AUC(12–24h) referring to the daytime.
No hypothesis testing was planned, and the treatment
comparison was exploratory only. The statistical model in-
cluded ‘treatment’ and ‘period’ as fixed effects and ‘patient’
as a random effect. ‘Study baseline’ for FEV1, defined as
pre-treatment values measured at the randomization visit in
the evening, was included as a covariate, which was ac-
complished by using compound symmetry covariance
structure for within-patient variation.
For morning and evening peak expiratory flow, only the
assessments of the last week of each 4-week treatment pe-
riod were evaluated. Baseline was defined as the mean of the
values obtained during the last week of the 28-day screening
period before randomization.
Descriptive statistics were calculated for tiotropium
concentrations in plasma and urine as well as PK parame-
ters. Mean PK profiles are presented as geometric means,
using the planned blood-sampling time.
Safety and tolerability, assessed by an analysis of adverse
events, were descriptive only.
Results
Baseline demographics, disease characteristics,
and disposition
A total of 98 patients were randomized, and all patients
were included in the full analysis set. One patient was
withdrawn from the study before entering the second 4-
week period (once-daily 5lg period) due to cervical carci-
noma, meaning no data were available (Fig. 3). A subset of
35 patients was included in the PK analyses.
Overall, the majority of patients were male (55.1%), with
a mean age of 43.8 years and a mean duration of asthma of
20.2 years, and 69.4% of patients had never smoked (Table 1).
In the 30.6% of patients who were ex-smokers, the mean
number of pack-years was 4.8. During the treatment period,
all patients continued their ICSmedication: budesonide (48.0%
of the patients) and fluticasone (28.6% of the patients) were
the most frequently used (mean budesonide or equivalent
dose – standard deviation at randomization: 661– 252lg).
Efficacy
Both daily tiotropium dosing regimens provided an im-
provement in FEV1 from study baseline. The adjusted
Table 1. Baseline Patient Demographics
and Disease Characteristics
Total (N = 98)
Age, yearsa 43.8 – 12.1
Sex, n (%)
Male 54 (55.1)
Female 44 (44.9)
Body mass index, kg/m2 a 27.7 – 4.8
Smoking status
Never smoked, n (%) 68 (69.4)
Ex-smoker, n (%) 30 (30.6)
Pack-yearsa 4.8 – 2.7
Duration of asthma, yearsa 20.2 – 12.6
Pre-bronchodilator FEV1 at screening
a,b
Actual (mL) 2518 – 660
% of predicted 73.7 – 8.6
Pre-bronchodilator FEV1 at randomization
(study baseline)a,c
Actual (mL) 2634 – 773
% of predicted 76.7 – 11.7
Pre-bronchodilator FVC at randomization
(study baseline)a,c
Actual (mL) 3964 – 1027
% of predicted 97.0 – 12.3
ACQ-7 scorea,d 2.5 – 0.7
ICS dose of stable maintenance
treatment, lga,e
661 – 252
Treated set.
aValues are mean – standard deviation. bVisit 1 (screening),
measured 10–15min after inhalation of four puffs of salbutamol
(100lg per actuation). cVisit 2 (randomization), measured 10min
before inhalation of the first dose of study drug. dACQ-7 questions 1–6
were self-administered by patients and preceded any discussion with a
healthcare professional. ACQ-7 question 7 was completed after pre-
dose MasterScope spirometry. eBudesonide or equivalent dose.
ACQ-7, seven-question Asthma Control Questionnaire; FEV1,
forced expiratory volume in 1 second; FVC, forced vital capacity;
ICS, inhaled corticosteroids.
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mean (standard error) FEV1 AUC(0–24h) response was 217
(31) mL following once-daily tiotropium 5 lg and 219 (31)
mL following twice-daily 2.5 lg. No difference was found
between the two daily dosing regimens: mean (standard
error) was -2 (18) mL (95% confidence interval: -38, 34)
(Table 2, Fig. 4).
For all secondary FEV1-based end points, the adjusted
means for once-daily tiotropium 5 lg and twice-daily 2.5 lg
were comparable, with no differences between the two daily
dosing regimens (Table 2). A diurnal variation in lung
function was observed, with FEV1 AUC(12–24h) responses of
243mL and 256mL for once-daily tiotropium 5 lg and
twice-daily 2.5 lg, compared with 192mL and 182mL, re-
spectively, for FEV1 AUC(0–12h) responses.
Morning and evening peak expiratory flow responses at
the end of each treatment period (calculated as weekly
mean) were comparable between the two tiotropium daily
dosing regimens, with no difference observed (Table 2).
Pharmacokinetics
PK parameters were assessed at steady state and are
shown in Table 3 and Figure 5. Geometric mean values of
pre-dose plasma concentrations of tiotropium at steady state
ranged between 1.43 pg/mL (5lg once daily) and 1.59 pg/mL
(2.5 lg twice daily). By contrast, tiotropium could not be
detected in pre-dose plasma samples, before administration
of the first dose of study treatment. Total exposures mea-
sured over the first 12 hours after dosing and over 24 hours
were comparable between the two tiotropium dosing regi-
mens. As expected, maximum plasma concentration values
following morning and evening dosing were lower (35% to
37%, respectively) for twice-daily tiotropium 2.5 lg than for
once-daily 5lg evening dosing. The cumulative urinary
excretion of tiotropium over 24 hours was similar for both
dosing regimens at steady state.
Tiotropium was rapidly absorbed, with a median time to
observed maximum plasma concentration value of 5 min-
utes post-dosing following once- or twice-daily dosing, and
a long half-life of around 30 hours. There was no difference
in the median time to observed maximum plasma concen-
tration following morning and evening dosing of tiotropium
2.5 lg; the maximum tiotropium plasma concentrations
were also comparable (Table 3).
Unexpected tiotropium plasma levels were observed in
six blood samples (0.9%) from two patients. These two
patients exhibited a second peak plasma concentration 12 h
10min and 13 h post-dosing following once-daily tiotropium
5 lg (at the time of scheduled placebo administration). In
one of the patients, tiotropium plasma concentrations re-
mained elevated for the subsequent blood samples collected
after this second maximum plasma concentration value
Table 2. Fev1 Auc(0–24h) Response, Secondary Fev1-based End Point Responses, and Mean Morning
and Evening PEF Responses (Last Week) at the End of the Two 4-week Treatment Periods
Treatment and parameter
Adjusted mean
responsea – SE
Adjusted differencea between treatments
Mean – SE 95% CI
FEV1 AUC(0–24h), mL
Tiotropium Respimat 5lg QD (n = 97) 217– 31 -2– 18 -38, 34Tiotropium Respimat 2.5 lg BID (n = 98) 219– 31
FEV1 AUC(0–12h), mL
Tiotropium Respimat 5lg QD (n = 97) 192– 31
10– 21 -32, 52Tiotropium Respimat 2.5 lg BID (n = 98) 182– 31
FEV1 AUC(12–24h), mL
Tiotropium Respimat 5lg QD (n = 97) 243– 33 -14– 18 -50, 22Tiotropium Respimat 2.5 lg BID (n = 98) 256– 33
Peak FEV1(0–24h), mL
Tiotropium Respimat 5lg QD (n = 97) 451– 31 -14– 18 -51, 23Tiotropium Respimat 2.5 lg BID (n = 98) 465– 31
Trough FEV1, mL
Tiotropium Respimat 5lg QD (n = 97) 207– 34
4– 32 -60, 68Tiotropium Respimat 2.5 lg BID (n = 98) 203– 33
Morning PEFb, L/min
Tiotropium Respimat 5lg QD (n = 96) 33– 6
2– 4 -6, 11Tiotropium Respimat 2.5 lg BID (n = 98) 31– 6
Evening PEFb, L/min
Tiotropium Respimat 5lg QD (n = 96) 34– 6 -0.3 – 4 -8, 8Tiotropium Respimat 2.5 lg BID (n = 98) 34– 6
Full analysis set.
aAdjusted for treatment, period, patient, and baseline. bBased on the last week before randomization.
Common baseline mean – standard deviation: FEV1 = 2634– 773mL. Common baseline mean – standard deviation: morning
PEF = 389– 121 L/min; evening PEF = 402– 123 L/min.
BID, twice daily; CI, confidence interval; FEV1, forced expiratory volume in 1 second; FEV1 AUC(0–12h), forced expiratory volume in
1 second area under the curve from 0 to 12 hours (night-time period); FEV1 AUC(0–24h), forced expiratory volume in 1 second area under
the curve from 0 to 24 hours; FEV1 AUC(12–24h), forced expiratory volume in 1 second area under the curve from 12 to 24 hours (daytime
period); PEF, peak exploratory flow; QD, once daily; SE, standard error.
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following morning dosing. Comparison of data with and
without the inclusion of these two patients in the analyses
with suspected sample contamination did not influence the
PK outcome of the trial (data not shown).
Safety and tolerability
The overall occurrence of adverse events was comparable
between the two tiotropium regimens (Table 4). A total of
18 patients (18.4%) reported adverse events during treatment
with once-daily tiotropium 5lg, and 19 patients (19.4%)
during treatment with twice-daily tiotropium 2.5lg. The
most frequently reported adverse events were nasopharyngitis
(both treatment periods, 4.1%) and headache (once-daily
tiotropium 5lg, 3.1%; twice-daily tiotropium 2.5lg, 2.0%).
Drug-related events were infrequent and occurred in two
patients (2.0%) during treatment with twice-daily tiotropium
2.5lg (dry mouth), and one patient (1.0%) during treatment
with once-daily tiotropium 5lg (headache). Serious adverse
events were reported in one patient (1.0%) while on treatment
FIG. 4. FEV1 response over 24 hours following the final once-daily and twice-daily
doses at the end of each 4-week treatment period (full analysis set). BID, twice daily;
FEV1, forced expiratory volume in 1 second; QD, once daily.
Table 3. Tiotropium Respimat Pharmacokinetic Parameters at Steady State
Tiotropium Respimat 5 lg QD Tiotropium Respimat 2.5 lg BID
Parameter n Geometric mean Geometric CV (%) n Geometric mean Geometric CV (%)
AUC(0–24h)ss, pg$h/mL 24 43.8 28.9 23 45.3 20.6
AUC(0–12h)ss, pg$h/mL 31 23.4 33.5 26 21.5 25.3
Cmax,ss, pg/mL 34 4.95 106 33 3.10 40.4
Cmax,ss,2, pg/mL – – – 34 3.23 50.8
Ae(0–24h)ss, ng 32 677 54.2 34 722 49.4
Pharmacokinetic subset (n = 35).
Ae(0–24h)ss, urinary excretion over 24 hours at steady state; AUC(0–12h)ss, area under the curve from 0 to 12 hours at steady state; AUC(0–
24h)ss, area under the curve over 24 hours at steady state; BID, twice daily; Cmax,ss, steady-state maximum plasma concentration after the
evening dose; Cmax,ss,2, steady-state maximum plasma concentration after the morning dose; CV, coefficient of variation; QD, once daily.
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with twice-daily tiotropium 2.5lg (cervical dysplasia and
cervical carcinoma in situ), which led to premature discon-
tinuation; this patient completed the 2.5lg treatment period
and was withdrawn before switching to tiotropium 5lg. No
fatal events were reported.
Discussion
The results of this study show that once-daily tiotropium
5 lg and twice-daily tiotropium 2.5 lg, both as add-on to
ICS, provide comparable bronchodilation over 24 hours, in
line with previous findings and with a comparable magni-
tude of the effect size.(10) For all end points, the responses
were comparable between tiotropium daily regimens, with
no numerical difference observed between dosing regimens.
Tiotropium 5 lg was administered once daily in the evening
during this study; however, similar results would be ex-
pected if the 5 lg dose was administered in the morning.
The diurnal variation observed in the 24-hour FEV1 profile
in both treatment groups has been reported previously(10,19)
and is attributed to a night-time increase, and subsequent
morning decrease, in parasympathetic activity with associ-
ated changes in bronchodilation, rather than a consequence
of tiotropium dosing.(20)
PK parameters are consistent with fast absorption and
long elimination time of tiotropium, with maximum plasma
concentrations reached within 5min, and half-life elimina-
tion time in the range of 30 h. The PK profile following both
dosing regimens was also similar and of the same magnitude
as previously reported,(10) with comparable AUC values
over 24 h observed in both studies, following once-daily 5lg
and twice-daily 2.5lg administrations. Similarly, maximum
plasma concentrations values for morning and evening dosing
were lower (35% to 37%, respectively) for twice-daily tio-
tropium 2.5lg than for once-daily 5lg evening dosing,
similar to the values noted in the previous PK study.(10)
Cumulative urinary excretion and area under the plasma
concentration curve both demonstrated comparable total tio-
tropium exposure following once-daily tiotropium 5lg and
twice-daily tiotropium 2.5lg dosing.
Unexpected plasma concentrations in some samples were
observed for two of the 35 patients in the once-daily tio-
tropium 5 lg subset reported here. Most sources of sample
FIG. 5. Geometric mean tiotropium plasma concentration–time profiles following
multiple inhalations to steady state of 5 lg via the Respimat inhaler by patients with
moderate persistent asthma. PK measurements performed 15min before evening admin-
istration, and after 2, 5, 7, 10, 15, and 30min and 1, 3, and 11.75 h (morning administration
12 hours following the evening dose), 12 hours +2, 5, 7, 10, 15, and 30min, and 13, 15,
and 23.75 h relative to the evening dose. Pharmacokinetic subset (n= 35). BID, twice
daily; QD, once daily.
Table 4. Overview of All Reported Adverse Eventsa
Tiotropium
Respimat
5lg QD
Tiotropium
Respimat
2.5 lg BID
n (%) (n= 98) (n = 98)
Any adverse event 18 (18.4) 19 (19.4)
Nasopharyngitis 4 (4.1) 4 (4.1)
Headache 3 (3.1) 2 (2.0)
Dysphonia 1 (1.0) 2 (2.0)
Rhinitis 1 (1.0) 2 (2.0)
Asthma worsening 2 (2.0) 0
Contusion 2 (2.0) 0
Cough 0 2 (2.0)
Dry mouth 0 2 (2.0)
Rash 1 (1.0) 1 (1.0)
Urticaria 1 (1.0) 1 (1.0)
Investigator-defined drug-related
adverse events
1 (1.0) 2 (2.0)
Adverse events leading to
discontinuation
0 1 (1.0)
Serious adverse events 0 1 (1.0)
Treated set.
aFrequency of adverse events that occurred in more than one
patient in any treatment group, sorted by preferred term and system
organ class.
BID, twice daily; QD, once daily.
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contamination in respiratory drug analysis are thought to
derive from sample handling or during device priming,(11)
which may have been the case for one unexpected tio-
tropium plasma level in our study (a second increase in
plasma concentration was observed 13 h post-dosing). Other
possible sources include: swapping of multiple samples
during processing at the site; tiotropium inhalation from the
evening instead of the morning Respimat inhaler; or in-
halation from other tiotropium sources. The observed in-
crease in tiotropium concentration in subsequent plasma
samples from one patient following scheduled inhalation
from the placebo Respimat inhaler indicates that the in-
correct inhaler was used, in this case the one containing
tiotropium. Therefore, there is a need to thoroughly instruct
patients and educate clinical site personnel to follow pro-
tocols rigorously when using two different inhalers on the
same day. In this study, the introduction of color-coded la-
beling to increase differentiation between morning and
evening inhalers, as well as detailed steps to prevent con-
tamination such as using separate rooms for priming of the
device and inhalation of the study drug, wearing gloves
when handling the Respimat inhaler, and thorough wash-
ing of hands (Supplementary Table 1), resulted in a low
number of unexpected PK results.
The extensive preventative steps applied at all stages of the
device-priming procedure and drug administration, sample
collection, and sample handling in this study, to avoid con-
tamination of blood and urine samples with tiotropium,
highlight the difficulties in ensuring there is no contamina-
tion, especially in multisite, multinational trials in Phase II or
Phase III settings. However, the approaches taken in the
present study indicate that contamination can be reduced to a
minimum when evaluating the PK of inhaled drugs.
To date, results from the current study and those reported
by Timmer et al.(10) are the only data from two large Phase
II clinical trials, conducted across multiple sites, to de-
scribe the PK profile of tiotropium in patients with asthma.
The strength of both studies lies in the large number of
different patients involved in two similarly designed
studies, which enabled us to assess the impact of two
dosing regimens on the 24-hour bronchodilation efficacy of
tiotropium. In addition, the current study demonstrates the
importance of using a trial protocol designed to both re-
duce errors caused by improper use of the inhaler and
minimize the risk of contamination, in large clinical trials
conducted across multiple sites.
Careful consideration should therefore be given when
performing clinical dosing studies of inhalation drugs.
Providing initial training to both clinical and laboratory staff
on best practices across trial centers could prove a useful
way of keeping the level of sample contamination low, as
well as ensuring consistency of practice. Similarly, clearly
labeled devices with a combination of simple shape and
color-coding could help patients ensure they use the correct
device at the correct time.
In this reported study, total tiotropium exposure over
24 hours was comparable between the two dosing regimens.
The observed bronchodilation efficacy over 24 hours was
similar with the once-daily 5lg and twice-daily 2.5lg dosing
regimens of tiotropium, as add-on to ICS therapy, supporting
the suitability of once-daily dosing to improve and sustain
lung function in adults with symptomatic asthma.
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